NIKKEI 225
27,821.76 -462.16 (-1.63%) HANG SENG
23,475.26 -376.98 (-1.58%) CRUDE OIL
65.28 -4.67 (-6.68%) GOLD FUTURES
1,776.30 -8.90 (-0.50%) DOW
34,626.78 -509.16 (-1.45%) BTC-GBP
43,871.26 -601.85 (-1.35%)
GlaxoSmithKline plc (GLAXF)
| Previous close | 19.89 |
| Open | 20.80 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 20.18 - 20.80 |
| 52-week range | 16.50 - 21.54 |
| Volume | |
| Avg. volume | 58,761 |
| Market cap | 106.789B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 18.25 |
| EPS (TTM) | 1.14 |
| Earnings date | N/A |
| Forward dividend & yield | 1.09 (5.49%) |
| Ex-dividend date | 18 Nov 2021 |
| 1y target est | N/A |
- Motley Fool
Why Vir Biotechnology Stock Is Soaring Today
Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.
- Motley Fool
Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb
In particular, GlaxoSmithKline (NYSE: GSK) and Bristol-Myers Squibb (NYSE: BMY) are two of the world's most preeminent pharmaceutical companies, but neither has consistently outperformed the market over the past five years. Right now, Bristol-Myers is in the doldrums. Over the past three years, its quarterly revenue has jumped 94.6% and quarterly net income has risen 33.3%.
- Zacks
Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas
Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.
